Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-120 (ivosidenib) plus azacitidine vs placebo plus azacitidine in untreated AML with IDH1 mutation
jRCT2051240135Phase 3Active, not recruiting
- Sponsor
- Servier
- Start
- Feb 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing AG-120 + azacitidine with Placebo + azacitidine (2 arms). Primary endpoint: Event-free survival. Started Feb 2019; status: active, not recruiting.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2051240135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240135.